← back to search

Ceyda Sönmez Wetherilt

Istanbul University-Cerrahpaşa · TR
Area of research
Oncology · Cancer Research
Research interest
Research interests include Breast Cancer Treatment Studies, Advanced Breast Cancer Therapies, HER2/EGFR in Cancer Research, and Cancer Immunotherapy and Biomarkers.
h-index
5
citations
305
works
16
NIH funding
primary concept
email

Recent publications

Prognostic Role of Androgen Receptor in Triple Negative Breast Cancer: A Multi-Institutional Study
Cancers 2019cited by 75position: middledoi
Tumor-infiltrating lymphocytes are significantly associated with better overall survival and disease-free survival in triple-negative but not estrogen receptor–positive breast cancers
Human Pathology 2017cited by 84position: middledoi
Multi-institutional study of nuclear KIFC1 as a biomarker of poor prognosis in African American women with triple-negative breast cancer
Scientific Reports 2017cited by 44position: middledoi
Stromal PD-L1 Expression Is Associated With Better Disease-Free Survival in Triple-Negative Breast Cancer
American Journal of Clinical Pathology 2016cited by 92position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Xiaoxian Li · Emory University3 papers (2016–2017)Uma Krishnamurti · Yale New Haven Hospital3 papers (2016–2017)Limin Peng · Emory University2 papers (2016–2017)Ritu Aneja · University of Alabama at Birmingham2 papers (2016–2017)Jing Yang · School of Phammacy:Ningxia Medical University2 papers (2016–2017)Jane Meisel · Emory University1 papers (2016–2016) · 1 papers (2017–2017) · 1 papers (2016–2016)Shristi Bhattarai · University of Alabama at Birmingham1 papers (2017–2017) · 1 papers (2017–2017) · 1 papers (2017–2017)Guilherme Cantuaria · Cornell University1 papers (2017–2017)Michelle D. Reid · Emory University1 papers (2017–2017)Karuna Mittal · Children's Healthcare of Atlanta1 papers (2017–2017) · 1 papers (2017–2017)Angela Ogden · University of Nottingham1 papers (2017–2017) · 1 papers (2017–2017)Toncred M. Styblo · Emory University1 papers (2016–2016)Remus Oşan · Gilead Sciences (United States)1 papers (2017–2017) · 1 papers (2017–2017)